Top 5 Small Molecule API CDMOs

Published: September 2026

Small molecule contract development and manufacturing organizations (CDMOs) have emerged as a critical component of the global pharmaceutical industry, supporting the development and commercialization of a wide range of conventional and complex small molecule drugs. Unlike biologics, small molecule APIs are typically produced through sophisticated chemical synthesis and require integrated capabilities across process development, route optimization, scale-up, manufacturing, purification, and stringent quality control. The increasing complexity of drug molecules and growing regulatory requirements have further strengthened the need for specialized manufacturing expertise and advanced production infrastructure.

The rising prevalence of chronic and acute diseases, expansion of pharmaceutical pipelines, and continued demand for generic and innovative small molecule therapies have significantly accelerated the need for reliable and scalable API manufacturing capabilities. At the same time, the industry is witnessing increasing demand for complex small molecule modalities, including highly potent APIs, oncology compounds, and other specialized drug substances, which require dedicated facilities, containment technologies, and technical expertise. These trends are creating significant opportunities for CDMOs with capabilities spanning early-stage development through commercial-scale manufacturing.

Additionally, pharmaceutical companies are increasingly adopting outsourcing strategies by partnering with CDMOs to access specialized technologies, reduce capital expenditure, improve manufacturing flexibility, and accelerate time-to-market. This has resulted in a highly competitive small molecule CDMO landscape, where leading players are differentiating themselves through integrated development and manufacturing capabilities, global production networks, advanced process technologies, and investments in capacity expansion. As pharmaceutical pipelines continue to expand and an increasing number of small molecule candidates progress toward commercialization, demand for outsourced API development and manufacturing services is expected to grow, further strengthening the role of CDMOs in the global small molecule pharmaceutical supply chain.

Roots Analysis has conducted an exhaustive study of the Small Molecule API Manufacturing featuring the current market landscape and future opportunities for developers engaged in healthcare, over the span of next 9 years.

Top 5 Small Molecule API CDMOs

AbbVie Contract Manufacturing
Biocon
Catalent
Curia
Lonza

The figure below highlights leading Small Molecule API CDMOs:

Top 5 CDMOs to Watch Small Molecule API Manufacturing

Interested in exploring all 150+ small molecule API CDMOs, along with their recent initiatives?

Discover Below the Details on Top 5 Small Molecule API CDMOs:

Let us dive deep into the details of the top 5 small molecule API CDMOs. It is essential to note that the selection of top companies can differ substantially according to the defined criteria.

1. AbbVie Contract Manufacturing

Company Overview

AbbVie Contract Manufacturing provides small-molecule API development and manufacturing services, supporting programs from development through commercial production. Its capabilities include synthetic and fermentation-based APIs, complex chemistries, and high-potency APIs. The company operates API manufacturing sites in the US and Europe, with flexible production capabilities to accommodate different batch sizes and potencies.

	Company Name	Year of Establishment	Headquarters	Number of Employees
	AbbVie	2013	US	10,000+

Recent Developments

In February 2026, AbbVie Contract Manufacturing announced a USD 380 million investment with the aim of building two new API manufacturing facilities in North Chicago. The facilities will incorporate advanced manufacturing technologies and AI to support next-generation sequencing and obesity medicines.

To know more about the recent initiatives of AbbVie Contract Manufacturing and small molecule API CDMOs, access full report.

2. Biocon

Company Overview

Biocon is a global manufacturer of complex small-molecule APIs, with expertise spanning synthetic chemistry, fermentation, peptide synthesis, chromatography, and high-potency APIs. Its manufacturing infrastructure supports large-scale production and global supply, backed by extensive GMP and regulatory compliance experience. Biocon focuses on complex and differentiated APIs across areas including oncology, metabolic disorders, and other therapeutic categories.

	Company Name	Year of Establishment	Headquarters	Number of Employees
	Biocon	1978	India	5,001-10,000

Recent Developments

In January, Biocon completed a rs 4,150 crore qualified institutional placement with an aim to strengthen its financial position and supports its broader growth and investment strategy, including its generics and small-molecule business.

To know more about the recent initiatives of Biocon and small molecule API CDMOs, access full report.

3. Catalent

Company Overview

Catalent is a global CDMO providing pharmaceutical development and manufacturing services across the product lifecycle. Within small molecules, its capabilities include development and manufacturing of drug substances and APIs, supported by a global network of manufacturing facilities and technical expertise. The company serves pharmaceutical and biotechnology customers from development through commercial supply.

	Company Name	Year of Establishment	Headquarters	Number of Employees
	Catalent	2007	US	10,000+

Recent Developments

In January 2026, Catalent highlighted its small-molecule CDMO capabilities and advanced manufacturing technologies, covering development through commercial manufacturing.

To know more about the recent initiatives of Catalent and small molecule API CDMOs, access full report.

4. Curia

Company Overview

Curia is a small-molecule CDMO offering process development and cGMP manufacturing of APIs, regulatory starting materials, and intermediates from preclinical through commercial stages. Its capabilities include complex chemistry, high-potency and cytotoxic APIs, sterile APIs, controlled substances, and specialized chemical processes. Curia operates a global manufacturing network with facilities across the US, Europe, and India.

	Company Name	Year of Establishment	Headquarters	Number of Employees
	Curia	1991	US	1,001-5,000

Recent Developments

In May 2026, Curia completed USD 4 million upgrade of two API aseptic manufacturing suites in Valladolid, Spain. The upgrades bring the facilities in line with the latest EU GMP Annex 1 requirements and strengthen Curia's sterile API manufacturing capabilities.

To know more about the recent initiatives of Curia and small molecule API CDMOs, access full report.

5. Lonza

Company Overview

Lonza is a leading global CDMO offering integrated small-molecule drug substance/API development and manufacturing services from early development through commercial supply. Its capabilities cover complex small molecules, highly potent APIs, process development, scale-up, and commercial manufacturing. Lonza leverages a global manufacturing network and more than four decades of experience in small-molecule development and manufacturing.

	Company Name	Year of Establishment	Headquarters	Number of Employees
	Lonza	1897	Switzerland	10,000+

Recent Developments

In May 2026, Lonza reported sustained business momentum in Q1 2026 and continued investment plans across its manufacturing network. The company secured multiple integrated drug-product contracts, demonstrating continued demand for its outsourced manufacturing services.

To know more about the recent initiatives of Lonza and small molecule API CDMOs, access full report.

What About Other Small Molecule API Manufacturers Around the World?

The above article features the top small molecule API CDMOs selected from a pool of over 150 manufacturers that we have compiled. If you're interested, you can download the Sample Report on this topic by Roots Analysis. For personalized assistance in identifying the most relevant solutions based on your specific criteria, please don't hesitate to reach out to us at sales@rootsanalysis.com.

Sources: